Has Beng Fuh received payments from drug or device companies?

Yes. Drug and device makers reported $34,897 in general payments to Beng Fuh across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Beng Fuh did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Beng Fuh come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Beng Fuh

Pediatric Hematology-Oncology · Greenville, NCNPI 1134339369

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 32.7% of the total.

$34,897in general payments, 2019–2025

Across 71 payments — averaging $491.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$11K
Bayer$8K
Pfizer$8K
Global Blood Therapeutics, Inc.$2K
CSL Behring$2K
Sanofi$1K
plus $2K from 5 others

$2,273,492in research payments, 2019–2025

Across 609 payments — averaging $3733.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$930K
Pfizer$603K
Global Blood Therapeutics, Inc.$262K
Daiichi Sankyo Inc.$242K
Bayer$84K
Novo Nordisk AS$66K
plus $86K from 4 others

What the payments were for

Consulting fees$17,62050%
Speaking & faculty fees$7,58022%
Travel & lodging$7,11920%
Food & beverage$2,4197%
Education$1600%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	9	$11,409
Bayer	26	$8,271
Pfizer	10	$8,151
Global Blood Therapeutics, Inc.	1	$2,350
CSL Behring	10	$1,896
Sanofi	3	$1,250
Novartis	7	$1,189
Terumo BCT, Inc.	1	$114
Genentech USA, Inc.	2	$101
Takeda Pharmaceuticals U.S.A., Inc.	1	$100
Emmaus Medical, Inc.	1	$65

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXBRYTA$10,144
Jivi$7,503
ADAKVEO$826
Spectra Optia$114
VONVENDI$100

How this compares

$34,897 in reported general payments places this provider in the 80th percentile of 57 pediatric hematology-oncology providers in North Carolina.

See all pediatric hematology-oncology providers in North Carolina →

Other pediatric hematology-oncology in Greenville

Prarthana Bangalore ParthasarathyGreenville$413
Andrea WhitfieldGreenville$101
George HucksGreenville$91
Rachael DavisGreenville$49
Cathleen CookGreenville$48
Javier OesterheldCharlotte$140K
Paulette BryantCharlotte$126K
Alex GeorgeWinston Salem$92K
Joanne KurtzbergDurham$72K
Kris MahadeoDurham$67K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →